Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InSpe Bio is a French biotechnology company developing a proprietary platform for In-cell Protein Synthesis (ICPS). Spun out from the Institut Curie, the company's technology enables the production of complex and "difficult-to-express" proteins by leveraging the internal machinery of cells. This platform has broad applications in biomanufacturing, research tools, and potentially as a therapeutic delivery system for protein-based medicines. InSpe Bio aims to revolutionize how therapeutic proteins are produced and delivered, particularly for targets that are currently inaccessible via standard recombinant methods. The company is currently focused on scaling its platform and establishing partnerships within the pharmaceutical industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on INSPE.